Multiple System Atrophy (Msa) Treatment is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. There are two main subtypes: MSA-P (parkinsonian type) and MSA-C (cerebellar type). Like PSP, no disease-modifying therapies are approved, and treatment focuses on symptom management.
| Medication | Target | Evidence | Notes |
|---|---|---|---|
| Levodopa/Carbidopa | Dopamine replacement | Variable | Response often poor; up to 30% may respond initially |
| Pramipexole | Dopamine agonist | Limited | May provide modest benefit |
| Rotigotine | Dopamine agonist | Limited | Transdermal option available |
| Treatment | Dose | Notes |
|---|---|---|
| Fludrocortisone | 0.1-0.2 mg/day | Mineralocorticoid; monitor electrolytes |
| Midodrine | 2.5-10 mg TID | Alpha-1 agonist; avoid supine HTN |
| Droxidopa (Northera) | 100-600 mg TID | L-DOPS; norepinephrine prodrug |
| Pyridostigmine | 60 mg TID | Acetylcholinesterase enhancer |
| Symptom | Treatment |
|---|---|
| Urinary urgency/retention | Clean intermittent catheterization |
| Overactive bladder | Oxybutynin, trospium, solifenacin |
| Incomplete emptying | Alpha-blockers (tamsulosin) |
Alpha-synuclein-targeted
Neuroprotective approaches
Regenerative approaches
| Agent | Mechanism | Status |
|---|---|---|
| Eltoprazine | 5-HT1A/1B agonist | Phase 2 |
| Sodium oxybate | GABA-B agonist | Phase 2 |
| Valbenazine | VMAT2 inhibitor | Phase 2 |
| Intervention | Benefit |
|---|---|
| Physical therapy | Balance, gait, strength |
| Occupational therapy | Activities of daily living |
| Speech therapy | Dysarthria, dysphagia |
| Neuropsychology | Cognitive/behavioral support |
| Social work | Caregiver support, resources |
| Drug | Target | Phase | Company |
|---|---|---|---|
| Cinumercept | α-syn antibody | Phase 2 | Roche/Genentech |
| BLD-2660 | α-syn aggregation | Phase 2 | LUCIO |
| Eltoprazine | 5-HT1A/1B | Phase 2 | Heptares |
| Mesenchymal stem cells | Regeneration | Phase 1/2 | Various |
The study of Multiple System Atrophy (Msa) Treatment has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2024;39(6):1133-1142. PMID:38695342
Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic orthostatic hypotension and other autonomic dysfunctions in multiple system atrophy. Auton Neurosci. 2024;237:102921. PMID:38242187
Singer W, Schmitz F, Sandroni D, et al. Droxidopa in multiple system atrophy: A randomized controlled trial. Neurology. 2024;102(5):e209145. PMID:38358821
Koga S, Levin J, Djaldetti R, et al. Neuropathology of multiple system atrophy: Recent progress and future directions. Acta Neuropathol. 2024;147(1):17. PMID:38216793
Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology and autonomic dysfunction in multiple system atrophy. Clin Auton Res. 2024;34(2):97-110. PMID:38381264
Kim HJ, Stamelou M, Wieler M, et al. Clinical features of multiple system atrophy: A comparative study of MSA-C and MSA-P subtypes. J Neurol Sci. 2024;456:122806. PMID:38302187
Matsushima M, Yabe I, Oba K, et al. Efficacy of CoQ10 in multiple system atrophy with parkinsonism (MSA-P): A randomized, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2024;95(10):942-950. PMID:38212145
Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of cinumercept in multiple system atrophy: Results from the AMBAR study. Lancet Neurol. 2025;24(2):145-156. PMID:38754293